Cantor Fitzgerald Reiterates “Overweight” Rating for ADMA Biologics (NASDAQ:ADMA)

Cantor Fitzgerald restated their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA) in a report issued on Friday, Benzinga reports. The firm currently has a $20.00 price target on the biotechnology company’s stock.

Several other research firms also recently issued reports on ADMA. HC Wainwright upped their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a buy rating in a report on Monday, August 12th. Mizuho raised their price target on ADMA Biologics from $12.00 to $14.00 and gave the company a buy rating in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $15.50.

ADMA Biologics Trading Up 1.2 %

Shares of NASDAQ:ADMA opened at $19.98 on Friday. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $4.63 billion, a PE ratio of -999.00 and a beta of 0.61. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $20.16. The firm has a fifty day moving average price of $15.77 and a 200 day moving average price of $11.00.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the prior year, the company posted ($0.02) EPS. The firm’s revenue was up 78.4% on a year-over-year basis. Analysts expect that ADMA Biologics will post 0.49 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 in the last ninety days. Company insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. grew its holdings in shares of ADMA Biologics by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,465 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in ADMA Biologics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock worth $7,398,000 after buying an additional 27,357 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of ADMA Biologics by 49.8% during the fourth quarter. BNP Paribas Financial Markets now owns 290,605 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 96,653 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of ADMA Biologics by 17.7% in the fourth quarter. Principal Financial Group Inc. now owns 158,634 shares of the biotechnology company’s stock valued at $717,000 after acquiring an additional 23,844 shares during the last quarter. Finally, Oxford Asset Management LLP acquired a new position in shares of ADMA Biologics in the 4th quarter worth approximately $83,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.